David A. Siegel 4 D Molecular Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 549,700 shares of FDMT stock, worth $5.96 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

549,700

Previous 743,400 26.06%

Holding current value

$5.96 Million

Previous $2.76 Million 67.8%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$3.95 - $8.44 $765,115 - $1.63 Million	-193,700 Reduced 26.06%	549,700 $4.63 Million
Q2 2025 Aug 14, 2025	BUY	$2.51 - $4.79 $635,030 - $1.21 Million	253,000 Added 51.59%	743,400 $2.76 Million
Q1 2025 May 15, 2025	BUY	$3.23 - $6.6 $1.18 Million - $2.4 Million	364,000 Added 287.97%	490,400 $1.58 Million
Q4 2024 Feb 14, 2025	BUY	$5.3 - $10.41 $548,550 - $1.08 Million	103,500 Added 451.97%	126,400 $704,000
Q3 2024 Nov 14, 2024	BUY	$10.81 - $27.22 $247,549 - $623,338	22,900 New	22,900 $247,000

Q3 2023 Nov 14, 2023	SELL	$12.64 - $19.76 $317,845 - $496,884	-25,146 Reduced 22.38%	87,200 $1.11 Million
Q2 2023 Aug 14, 2023	BUY	$15.16 - $23.26 $187,165 - $287,167	12,346 Added 12.35%	112,346 $2.03 Million
Q1 2023 May 15, 2023	BUY	$15.45 - $23.19 $1.2 Million - $1.81 Million	77,900 Added 352.49%	100,000 $1.72 Million
Q4 2022 Feb 14, 2023	BUY	$6.85 - $25.46 $151,385 - $562,666	22,100 New	22,100 $490,000

Others Institutions Holding FDMT

# of Institutions

137

Shares Held

40.5M

Call Options Held

70.6K

Put Options Held

13.1K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $351M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account